Table 3.
Mean global HRQoL scores in AML survivors, stratified by measurement tool
| Study | AML survivors |
|---|---|
| Mean score | |
| Cancer- or leukemia-specific instruments | |
| EORTC QLQ-C30a | |
| Bieri 2008 | 67.9 |
| Leunis 2014 | 75.3 |
| Messerer 2008 | 69.8 |
| Watson 2004b | 80 |
| FACT-G | |
| Bieri 2008 | 77.5 |
| Generic instruments | |
| EQ-5D utility | |
| Leunis 2014 | 0.8 |
| EQ VAS | |
| Leunis 2014 | 74.6 |
| Slovacek 2006 | 67.5 |
| SF-12 or SF-36 physical | |
| Schultz 2013 | 49.9 |
| SF-12 or SF-36 mental | |
| Schultz 2013 | 50.7 |
AML acute myeloid leukemia, EQ-5D European Quality of Life-5 Dimensions, EORTC European Organization for Research and Treatment of Cancer, FACT Functional Assessment of Cancer Therapy, Leu leukemia, QLQ Quality of Life Questionnaire, SF short form, VAS visual analog scale
aSherman et al. utilized the EORTC QLQ-C30 instrument, but did not report mean/median values, and the study was not included in this table
bScores were reported as percent of patients who reported problems in the global domain